{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:49:41Z","timestamp":1782107381260,"version":"3.54.5"},"reference-count":51,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>The prognosis of peripheral T\u2010cell non\u2010Hodgkin lymphomas (PTCL) is dismal, particularly in the relapsed\/refractory (r\/r) setting, where 3\u2010year overall survival (OS) is 20%\u201330%. No superior second\u2010line therapy for PTCL has been universally established, and durable remissions rely on consolidation with allogeneic haematopoietic stem cell transplantation (alloHSCT). Enhancing response rates to salvage therapy is, therefore, crucial to increase transplant eligibility. We retrospectively evaluated the efficacy of bendamustine, gemcitabine and vinorelbine combination (BeGeV) in 24 consecutive patients with r\/r PTCL treated at our centre since 2017. BeGeV achieved an overall response rate (ORR) of 66% and a complete remission rate (CRR) of 41%. After a median follow\u2010up of 41.8\u2009months, 1\u2010year progression\u2010free survival (PFS) and OS were 37.5% and 58.3% respectively. Outcomes differed by histology: PTCL not otherwise specified (PTCL\u2010NOS) showed inferior responses (ORR 41%, CRR 16%) compared with T\u2010follicular helper lymphomas (PTCL\u2010TFH; ORR 100%, CRR 75%) and systemic anaplastic large cell lymphoma (sALCL; ORR 75%, CRR 50%). Survival analyses confirmed substantial differences across subtypes, with 12\u2010month PFS and OS rates of 8.3% and 41.7% for PTCL\u2010NOS, 50% and 75% for sALCL and 75% and 75% for PTCL\u2010TFH respectively. Despite the limitations of small sample size and retrospective design, this study provides preliminary evidence supporting BeGeV as a potential bridge to alloHSCT in r\/r PTCL\u2010TFH and sALCL.<\/jats:p>","DOI":"10.1111\/bjh.70292","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:40:07Z","timestamp":1769064007000},"page":"916-925","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T\u2010cell lymphomas: A retrospective single\u2010centre experience"],"prefix":"10.1111","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-6952","authenticated-orcid":false,"given":"Filippo","family":"Bagnoli","sequence":"first","affiliation":[{"name":"Department of Oncology and Hematology IRCCS Humanitas Research Hospital  Rozzano Milan Italy"},{"name":"Department of Biomedical Sciences Humanitas University  Pieve Emanuele Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3043-4689","authenticated-orcid":false,"given":"Jacopo","family":"Calabrese De Feo","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology IRCCS Humanitas Research Hospital  Rozzano Milan Italy"},{"name":"Department of Biomedical Sciences Humanitas University  Pieve Emanuele Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ricci","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology IRCCS Humanitas Research Hospital  Rozzano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2272-7908","authenticated-orcid":false,"given":"Francesco","family":"Corrado","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology IRCCS Humanitas Research Hospital  Rozzano Milan Italy"},{"name":"Department of Biomedical Sciences Humanitas University  Pieve Emanuele Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1378-6896","authenticated-orcid":false,"given":"Daniele","family":"Mannina","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology IRCCS Humanitas Research Hospital  Rozzano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-7550","authenticated-orcid":false,"given":"Daoud","family":"Rahal","sequence":"additional","affiliation":[{"name":"Pathology Unit IRCCS Humanitas Research Hospital  Rozzano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3258-0727","authenticated-orcid":false,"given":"Arturo","family":"Bonometti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences Humanitas University  Pieve Emanuele Milan Italy"},{"name":"Pathology Unit IRCCS Humanitas Research Hospital  Rozzano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9419-8964","authenticated-orcid":false,"given":"Marcello","family":"Rodari","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit IRCCS Humanitas Research Hospital  Rozzano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9587-7870","authenticated-orcid":false,"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[{"name":"Biostatistic Unit, Humanitas Cancer Center IRCCS Humanitas Research Hospital  Rozzano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4117-7991","authenticated-orcid":false,"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology IRCCS Humanitas Research Hospital  Rozzano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmelo","family":"Carlo\u2010Stella","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology IRCCS Humanitas Research Hospital  Rozzano Milan Italy"},{"name":"Department of Biomedical Sciences Humanitas University  Pieve Emanuele Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology IRCCS Humanitas Research Hospital  Rozzano Milan Italy"},{"name":"Department of Biomedical Sciences Humanitas University  Pieve Emanuele Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282716"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15258"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_12_6_1","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first\u2010line therapy in poor\u2010risk peripheral T\u2010NHL [Internet]","volume":"137","author":"Schmitz N","year":"2021","journal-title":"Blood"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015114"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx787"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01687"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01780-1"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14477"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000500666"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25463"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00899"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00589-2"},{"key":"e_1_2_12_18_1","unstructured":"DwyerM.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines)T\u2010cell lymphomas. NCCN Guidelines for Patients.2024. Available from:www.nccn.org\/patients"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv201"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049"},{"issue":"2","key":"e_1_2_12_21_1","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase\u2010positive lymphoma patients","volume":"106","author":"Passerini CG","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003971"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007538"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009004"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009445"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14473"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.07.027"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010020\u201001133\u20105"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu515"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005899"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0696-z"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7285"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10764"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp508"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00102-9"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4466"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000984"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_12_42_1","unstructured":"U.S. Department of Health and Human Services.Common Terminology Criteria for Adverse Events(CTCAE)version 5.0.2017."},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24992"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165948"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008524"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015787"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.719615"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1738-9"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071137"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1654100"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-24"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07233-2"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70292","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70292","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:42:54Z","timestamp":1782106974000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/bjh.70292"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70292","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"2025-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}